Best R&D Funding Routes in the UK (2026)

Executive summary

Research and development is the area of UK funding where the public-sector intervention is deepest, the menu of instruments is widest, and the interactions between them are most consequential. A UK company that designs its R&D funding stack carefully can routinely recover 40% to 60% of its annual R&D spend through a combination of Innovate UK grant funding, the merged RDEC tax-relief regime, and, where applicable, the 10% effective rate of corporation tax on patented income offered by Patent Box. A company that designs its stack badly can lose access to one instrument by virtue of having applied for another.

This report sets out our editorial view of the strongest R&D funding routes available in the UK in 2026, the way the main instruments interact, and the order in which a typical innovation-led company should engage them. It is intended as a strategic primer for founders, finance leaders and innovation managers, and as a reference point for advisers. It does not replace specialist tax advice; the interactions between grant funding and tax relief are subject to statute and to HMRC interpretation, and material decisions should always be reviewed with a qualified R&D tax-relief practitioner.

The UK R&D funding landscape

The UK public R&D-funding system rests on three pillars. The first is direct innovation funding, channelled primarily through Innovate UK, the nine research councils that together form UK Research and Innovation, and the National Institute for Health and Care Research (NIHR) on the health side. The second is the Catapult network — nine sector-focused technology and innovation centres, from the High Value Manufacturing Catapult and Digital Catapult to Cell and Gene Therapy, Energy Systems, Connected Places, Satellite Applications, Offshore Renewable Energy, Medicines Discovery, and Compound Semiconductor Applications — operated under the Catapult Network. The third is the tax-relief system operated by HMRC: the merged RDEC scheme, the enhanced R&D-intensive SME regime, and Patent Box.

The FundingAtlas catalogue currently lists 507 published programmes, of which roughly 120 are tagged against the “Innovation” or “R&D Tax & Reliefs” objectives. Live distributions and provider concentration are published in the UK innovation funding statistics page and the UK Funding Index 2026. What follows here is the editorial layer on top of that data.

Grants vs tax reliefs vs loans

The three principal shapes of UK R&D funding behave differently in time, in risk, and in eligibility. Grants pay forward: the company wins a competitive award, claims costs as they are incurred, and is reimbursed up to the agreed intervention rate (commonly 50% to 70% for SMEs). Tax reliefs pay backward: the company claims at year-end against eligible R&D spend already incurred, either as a corporation-tax credit or — for loss-making companies — as a partially repayable cash credit. Loans bridge the two: Innovate UK Innovation Loans and similar facilities provide patient capital at below-market rates to fund the later, more capital-intensive stages of R&D commercialisation.

The trade-off matters because the three instruments interact. An Innovate UK grant counts, in most configurations, as notified state aid, and notified state aid received in respect of an R&D project disqualifies that project from the historically more generous SME R&D Tax Relief regime; the project must instead be claimed under the merged RDEC scheme. The cash gap between SME relief and RDEC is material, and is one of the most common surprises that catches first-time R&D-grant winners. Our comparisons R&D Tax vs Smart Grants and Innovation Loans vs R&D Tax Relief set out the maths in detail, and the decision guide R&D Tax vs grant walks through the choice on a project-by-project basis.

Best routes by business maturity

University-linked teams and spinouts

For research-led teams emerging from a UK university, the most appropriate first programme is almost always ICURe. ICURe is delivered by the University of Bristol on behalf of Innovate UK and pays a small team to spend three months in the market, talking to potential customers and building the evidence base needed to determine whether a discovery is a business. Teams that complete ICURe well are eligible for an Innovate UK follow-on award designed to fund the next stage of commercialisation. ICURe is a near-mandatory step for spinout founders who want to keep equity unallocated for as long as possible.

Early-stage businesses with active R&D

For startups in their first two to three years that are actively developing novel technology, the centre of gravity is the Innovate UK Smart Grant. Smart Grants are the largest single source of open, sector-agnostic R&D funding for UK SMEs. They are highly competitive — assessment scores in the high 7s out of 10 are generally needed to be funded — but they reward genuine technical novelty and a clear commercial plan in equal measure. Companies that have not yet built the in-house capability to deliver a Smart Grant project on their own should consider applying jointly with a Catapult or university partner, both to strengthen the application and to access equipment and expertise that would otherwise be prohibitive to acquire.

Scaling SMEs

For scaling SMEs with an established R&D function, the most important questions move from “what can we win?” to “how do we optimise the stack?”. The strongest combinations we see in our advisor-reviewed catalogue typically pair an Innovate UK Smart Grant or sector-themed Innovate UK competition with an Innovation Loan to fund the later, scale-up phase of the same programme of work. Companies engaged in the manufacturing sector should layer in Made Smarter Innovation for digitalisation of operations. Companies in health, life sciences and adjacent fields should engage NIHR early: NIHR's i4i programme and the Invention for Innovation pipeline are particularly well-suited to medtech and health-tech SMEs that need clinical evidence.

Mature R&D-intensive companies

For mature R&D-intensive companies, the centre of gravity shifts decisively to the tax-relief side of the system. The merged RDEC regime provides a uniform above-the-line credit on qualifying R&D expenditure, and the enhanced R&D-intensive SME regime provides a higher rate of relief for loss-making SMEs whose qualifying R&D exceeds the statutory threshold of total expenditure. Patent Box sits alongside these and reduces the effective rate of corporation tax to 10% on profits attributable to qualifying patents — a substantial benefit for companies whose innovation cycle results in granted IP. Our comparison Patent Box vs RDEC sets out the interaction in detail.

The strongest UK R&D programmes

• Innovate UK Smart Grants — open-topic flagship competition, typically £100k–£500k per project for small companies.
• Innovate UK Innovation Loans — patient debt for later-stage commercial R&D up to £2m.
• ICURe — structured market-discovery and commercialisation programme for university-linked teams.
• Knowledge Transfer Partnerships — co-funded academic-business projects of one to three years.
• R&D Tax Relief (SME & merged scheme) — annual tax credit on qualifying R&D spend.
• RDEC — above-the-line R&D Expenditure Credit; default route for large companies and grant-supported projects.
• Patent Box — 10% effective rate of corporation tax on profits attributable to qualifying patents.
• Made Smarter Innovation — flagship UK manufacturing-digitalisation R&D programme.
• Horizon Europe (UK participation) — access to European collaborative R&D consortia, including EIC Accelerator and Pathfinder.
• Net Zero Innovation Portfolio — the largest pool of UK clean-energy R&D competitions, run by DESNZ.

Innovate UK vs UKRI vs NIHR vs Catapults

A persistent source of confusion for first-time R&D applicants is the relationship between the major UK public funders of innovation. The simplest mental model is that UKRI is the umbrella under which the nine national research councils and Innovate UK sit; Innovate UK is the council inside UKRI that funds business-led innovation; the other councils predominantly fund discovery-led research carried out in universities, with businesses participating as partners; NIHR sits outside UKRI and funds applied health and care research; and the Catapult Network provides delivery infrastructure — facilities, equipment and expertise — that companies use to do the work funded through the other channels.

Companies that are unclear which funder is the right starting point should generally start with Innovate UK and engage a Catapult as a delivery partner. Companies that are working with universities should engage the relevant research council via their academic partner. Health and care companies should engage NIHR. The decision guide Should I engage a Catapult? walks through the trigger conditions in detail.

Common eligibility patterns

UK R&D funders consistently reward four eligibility attributes. The first is genuine technical novelty: the project must represent an advance in the field beyond the publicly available state of the art, not merely a new feature of an existing product. The second is project structure: defined deliverables, work packages, milestones, risks and budget at the level of individual cost categories. The third is delivery credibility: a named team with relevant prior experience, and, where the project is complex, named partners with complementary expertise. The fourth is commercial route to market: a coherent story about how the R&D, if successful, will translate into UK economic benefit.

On the tax-relief side, eligibility is governed by HMRC's published guidelines on what constitutes qualifying R&D for tax purposes (the so-called BEIS/DSIT guidelines). The single most common reason R&D Tax Relief claims are rejected or reduced on enquiry is that the underlying technical narrative does not establish a “competent professional” judgement that there was scientific or technological uncertainty. Companies should always document their reasoning contemporaneously.

Common mistakes

The mistakes we see most often are interaction mistakes. Companies claim SME R&D Tax Relief on projects that included a notified state-aid grant component, and have the claim reduced by HMRC. Companies apply for Innovate UK funding for projects that are functionally product development and are scored down on the “innovation” dimension. Companies start their R&D Tax Relief claim three months before the corporation-tax filing deadline and find that they have not retained the documentation needed to support a robust claim. Companies obtain a granted patent on a peripheral aspect of their technology and assume that this is enough to elect into Patent Box, without going through the streaming and tracking process the regime requires.

A separate category of mistake is funder mis-targeting. Companies apply for a UKRI research council grant when they should have applied to Innovate UK, or apply to a Catapult open call when they should have been negotiating a fee-for-service technical engagement. The decision guide Which R&D funding route? sets out the prioritisation logic we recommend.

Frequently asked questions

What is the difference between Innovate UK and UKRI?

Innovate UK is the UK's national innovation agency and is one of the nine councils inside UK Research and Innovation (UKRI). Innovate UK funds business-led R&D and commercialisation; the other councils (EPSRC, BBSRC, MRC, ESRC, AHRC, STFC, NERC and Research England) fund predominantly academic and discovery research, often with business partners. Most companies start with Innovate UK and engage other councils when they are collaborating with universities.

Can I claim R&D Tax Relief and an Innovate UK grant on the same project?

Yes, but the interaction is non-trivial. For SME R&D Tax Relief, any notified state aid received for the project — including most Innovate UK grants — disqualifies the entire project from SME relief; you must instead claim under the merged RDEC scheme for that project. R&D tax-relief specialists routinely model this trade-off before companies apply.

Is Patent Box worth applying for if I am pre-revenue?

Patent Box reduces the corporation-tax rate on profits attributable to qualifying patents to 10%. If you are pre-revenue or loss-making, there is no immediate cash benefit; but securing the underlying patents and putting the streaming and tracking infrastructure in place now will pay off as soon as the business becomes profitable on patented income.

Are Catapults grant-givers?

Catapults are not primarily grant bodies. They are technology and innovation centres that provide access to equipment, expertise, testbeds and consortium-building, often co-funded by Innovate UK. They sometimes administer open calls and partner-finding competitions, but their main value to companies is hands-on technical collaboration.

What is a KTP and who is it for?

A Knowledge Transfer Partnership is a three-way arrangement between a UK business, a UK academic partner and a graduate or post-doc associate. Innovate UK co-funds the associate's salary and project costs for one to three years to deliver a strategic technical project the business could not deliver on its own. KTPs are particularly powerful for established SMEs that want to inject a defined R&D capability.

Should a software-only company apply to Innovate UK Smart Grants?

Yes, provided the project contains a genuine technological advance and not just product development. Innovate UK funds software projects across AI, cybersecurity, digital health, fintech, gaming and many other sub-sectors. The most common reason software applications fail is that they describe a commercial product rather than a research and development project.

Continue reading

For live data, see the UK innovation funding statistics page and the UK Funding Index 2026. The companion reports cover Best Funding for UK Startups and Best Net Zero Funding Programmes.